{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:26:12Z","timestamp":1784903172712,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40265-022-01738-8","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T10:02:42Z","timestamp":1656928962000},"page":"1117-1125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Estetrol\/Drospirenone: A Review in Oral Contraception"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-7831","authenticated-orcid":false,"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahiya Y.","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"1738_CR1","unstructured":"United Nations, Department of Economic and Social Affairs, Population Division. Contraceptive use by method 2019: data booklet (ST\/ESA\/SER.A\/435). 2019."},{"issue":"24","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1001\/jama.2021.21392","volume":"326","author":"S Teal","year":"2021","unstructured":"Teal S, Edelman A. Contraception selection, effectiveness, and adverse effects. JAMA. 2021;326(24):2507\u201318.","journal-title":"JAMA"},{"issue":"11","key":"1738_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/17512433.2018.1536544","volume":"11","author":"C Bastianelli","year":"2018","unstructured":"Bastianelli C, Farris M, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation. Expert Rev Clin Pharmacol. 2018;11(11):1085\u201398.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"1738_CR4","first-page":"3","volume":"3","author":"M Mawet","year":"2021","unstructured":"Mawet M, Gaspard U, Foidart JM. Estetrol as estrogen in a combined oral contraceptive, from the first in-human study to the contraceptive efficacy. Eur Gynecol Obstet. 2021;3(1):3\u201321.","journal-title":"Eur Gynecol Obstet"},{"issue":"5","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"647","DOI":"10.2165\/00003495-200767050-00001","volume":"67","author":"A Motivala","year":"2007","unstructured":"Motivala A, Pitt B. Drospirenone for oral contraception and hormone replacement therapy. Drugs. 2007;67(5):647\u201355.","journal-title":"Drugs"},{"key":"1738_CR6","unstructured":"National Library of Medicine. Estetrol compound summary. 2022. https:\/\/pubchem.ncbi.nlm.nih.gov\/. Accessed 9 June 2022."},{"key":"1738_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/978-3-030-11355-1_12","volume-title":"Sex Steroids' effects on brain, heart and vessels ISGE series","author":"JM Foidart","year":"2019","unstructured":"Foidart JM, Gaspard U, Pequeux C, et al. Unique vascular benefits of estetrol, a native fetal estrogen with specific actions in tissues (NEST). In: Brinton R, Genazzani A, Simoncini T, Stevenson J (eds) Sex steroids' effects on brain, heart and vessels ISGE series. Springer, Cham 2019; Chapter 12:169\u201395."},{"issue":"6","key":"1738_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","volume":"102","author":"J Douxfils","year":"2020","unstructured":"Douxfils J, Klipping C, Duijkers I, et al. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters. Contraception. 2020;102(6):396\u2013402.","journal-title":"Contraception"},{"issue":"6","key":"1738_CR9","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.contraception.2021.03.003","volume":"103","author":"I Duijkers","year":"2021","unstructured":"Duijkers I, Klipping C, Kinet V, et al. Effects of an oral contraceptive containing estetrol and drospirenone on ovarian function. Contraception. 2021;103(6):386\u201393.","journal-title":"Contraception"},{"issue":"6","key":"1738_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3109\/13625187.2015.1044082","volume":"20","author":"IJ Duijkers","year":"2015","unstructured":"Duijkers IJ, Klipping C, Zimmerman Y, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015;20(6):476\u201389.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"4","key":"1738_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.contraception.2021.01.001","volume":"103","author":"C Klipping","year":"2021","unstructured":"Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103(4):213\u201321.","journal-title":"Contraception"},{"issue":"2","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.contraception.2016.08.018","volume":"95","author":"C Kluft","year":"2017","unstructured":"Kluft C, Zimmerman Y, Mawet M, et al. Reduced hemostatic effects with drospirenone-based oral contraceptives containing estetrol vs. ethinyl estradiol. Contraception. 2017;95(2):140\u20137.","journal-title":"Contraception"},{"issue":"2486","key":"1738_CR13","first-page":"1","volume":"13","author":"A Gallez","year":"2021","unstructured":"Gallez A, Blacher S, Maquoi E, et al. Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer. Cancers (Basel). 2021;13(2486):1\u201323.","journal-title":"Cancers (Basel)"},{"key":"1738_CR14","unstructured":"Mayne Pharma. Nextstellis (estetrol\/drospirenone) tablets: US prescribing information. 2021. https:\/\/dailymed.nlm.nih.gov\/. Accessed 9 Jun 2022."},{"issue":"10","key":"1738_CR15","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.15252\/emmm.201404112","volume":"6","author":"A Abot","year":"2014","unstructured":"Abot A, Fontaine C, Buscato M, et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328\u201346.","journal-title":"EMBO Mol Med"},{"key":"1738_CR16","unstructured":"European Medicines Agency. Lydisilka (estetrol\/drospirenone) tablets: EU assessment report. 2021. https:\/\/www.ema.europa.eu\/. Accessed 9 Jun 2022."},{"key":"1738_CR17","unstructured":"European Medicines Agency. Lydisilka (estetrol\/drospirenone) tablets: EU summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/. Accessed 9 Jun 2022."},{"issue":"4","key":"1738_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","volume":"94","author":"D Apter","year":"2016","unstructured":"Apter D, Zimmerman Y, Beekman L, et al. Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA). Contraception. 2016;94(4):366\u201373.","journal-title":"Contraception"},{"issue":"3","key":"1738_CR19","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","volume":"104","author":"MD Creinin","year":"2021","unstructured":"Creinin MD, Westhoff CL, Bouchard C, et al. Estetrol\u2013drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. Contraception. 2021;104(3):222\u20138.","journal-title":"Contraception"},{"issue":"1","key":"1738_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/1471-0528.16840","volume":"129","author":"K Gemzell-Danielsson","year":"2022","unstructured":"Gemzell-Danielsson K, Apter D, Zatik J, et al. Estetrol\u2013drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia. BJOG. 2022;129(1):63\u201371.","journal-title":"BJOG"},{"issue":"Suppl. 2","key":"1738_CR21","first-page":"386","volume":"155","author":"JT Jensen","year":"2021","unstructured":"Jensen JT, Kaunitz AM, Chen MJ, et al. Pooled phase-3 analysis of efficacy and safety of estetrol\/drospirenone combined oral contraceptive [abstract no. P0638]. Int J Gynaecol Obstet. 2021;155(Suppl. 2):386.","journal-title":"Int J Gynaecol Obstet"},{"issue":"4","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.contraception.2021.07.066","volume":"104","author":"AM Kaunitz","year":"2021","unstructured":"Kaunitz AM, Achilles SL, Jost M, et al. Bleeding patterns with use of an oral contraceptive containing estetrol and drospirenone: pooled analysis of phase-3 clinical trials [abstract no. P48]. Contraception. 2021;104(4):463.","journal-title":"Contraception"},{"issue":"(Suppl. 1)","key":"1738_CR23","first-page":"82","volume":"3","author":"K Gemzell-Danielsson","year":"2021","unstructured":"Gemzell-Danielsson K, Apter D, Jost M, et al. Bleeding patterns with estetrol\/drospirenone oral contraceptive by age, obesity status, and recent hormonal contraceptive use [abstract no. OP04]. Eur Gynecol Obstet. 2021;3(Suppl. 1):82.","journal-title":"Eur Gynecol Obstet."},{"issue":"4","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/13625187.2017.1336532","volume":"22","author":"D Apter","year":"2017","unstructured":"Apter D, Zimmerman Y, Beekman L, et al. Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control. Eur J Contracept Reprod Health Care. 2017;22(4):260\u20137.","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"1738_CR25","unstructured":"World Health Organization and Johns Hopkins Bloomberg School of Public Health. Center for Communication Programs. Family planning: a global handbook for providers: evidence-based guidance developed through worldwide collaboration, 3rd ed. (2018)."},{"key":"1738_CR26","unstructured":"Centers for Disease Control and Prevention. US selected practice recommendations (US SPR) for contraceptive use, 2016. 2022. https:\/\/www.cdc.gov\/. Accessed 9 Jun 2022."},{"key":"1738_CR27","unstructured":"Faculty of Sexual and Reproductive Healthcare. FSRH clinical guideline: combined hormonal contraception. 2020. https:\/\/www.fsrh.org\/. Accessed 9 Jun 2022."},{"issue":"3","key":"1738_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","volume":"122","author":"DF Archer","year":"2013","unstructured":"Archer DF, Nakajima ST, Sawyer AT, et al. Norethindrone acetate 10 milligram and ethinyl estradiol 1.0 micrograms as an ultra low-dose oral contraceptive. Obstet Gynecol. 2013;122(3):601\u20137.","journal-title":"Obstet Gynecol"},{"issue":"8","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"e1054","DOI":"10.1016\/S2214-109X(19)30265-7","volume":"7","author":"DF Archer","year":"2019","unstructured":"Archer DF, Merkatz RB, Bahamondes L, et al. Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. Lancet Glob Health. 2019;7(8):e1054\u201364.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.contraception.2014.03.018","volume":"90","author":"C Gerlinger","year":"2014","unstructured":"Gerlinger C, Trussell J, Mellinger U, et al. Different Pearl Indices in studies of hormonal contraceptives in the United States: impact of study population. Contraception. 2014;90(2):142\u20136.","journal-title":"Contraception"},{"issue":"1","key":"1738_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1530\/JOE-14-0549","volume":"224","author":"C Gerard","year":"2015","unstructured":"Gerard C, Blacher S, Communal L, et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol. 2015;224(1):85\u201395.","journal-title":"J Endocrinol"},{"issue":"Suppl. 1","key":"1738_CR32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/13697130802050340","volume":"11","author":"M Visser","year":"2008","unstructured":"Visser M, Foidart JM, Coelingh Bennink HJT. In vitro effects of estetrol on receptor binding, drug targets and human liver cell metabolism. Climacteric. 2008;11(Suppl. 1):64\u20138.","journal-title":"Climacteric"}],"updated-by":[{"DOI":"10.1007\/s40265-022-01760-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000}}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-022-01738-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-022-01738-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T16:18:01Z","timestamp":1660061881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-022-01738-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s40265-022-01738-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40265-022-01760-w","asserted-by":"object"}]},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"10 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40265-022-01760-w","URL":"https:\/\/doi.org\/10.1007\/s40265-022-01760-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Arnold Lee and Yahiya Y. Syed are salaried employees of Adis International Ltd\/Springer Nature, and declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}